• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

CBD Acne Skin Care Line Announced


Zelira Therapeutics has announced the launch of RAF FIVE acne treatment product.

Zelira Therapeutics, a company involved in the research and development of clinically validated cannabinoid medicines, announced the launch of RAF FIVE acne treatment products through its dermatology subsidiary Ilera Derm LLC ("Zelira Dermatology").1

The product line is to join the acne medication market which is valued at more than $11 billion worldwide and will consist of Wash Away gel cleanser acne treatment, Spot On acne treatment, Kick Off hydrating lotion broad spectrum SPF 30 sunscreen, After Hours moisturizing lotion acne treatment, and Clear the Way acne treatment pads, according to the press release. The ingredients in the products include hyaluronic acid, niacinamide, glycerin, thiotaine (derived from mushrooms), and peptides.

RAF FIVE is the only skin care line to feature Zylorma, a patent-pending acne fighting complex formulated with cannabidiol (CBD), salicylic acid, and additional botanical compounds developed by Zelira and Karyn Grossman, MD, a board-certified cosmetic dermatologist, New York, New York. 

Zylorma is used to fight bacteria and clogged pores associated with acne which also balances sebum production to combat and prevent acne breakouts. RAF FIVE uses pharmaceutical-grade CBD isolate derived from hemp and is tetrahydrocannabinol (THC)-free.

"I am excited to announce the launch of Zelira's Dermatology subsidiary and the RAF FIVE acne treatment line of skincare products. Dr. Grossman's reputation and experience in the cosmetic dermatology industry, combined with Zelira's peerless position in cannabinoid science, is the perfect combination,” said Oludare Odumosu, the CEO of Zelira Therapeutics and managing director, Philadelphia, Pennsylvania. “We have a unique opportunity to present a differentiated suite of proven acne treatment solutions to the US$11 billion acne treatment market where there is a high level of dissatisfaction with existing products and unmet needs. Zelira is staking a claim in the cannabinoid-based, over-the-counter skincare product market with our differentiated dermatology."

Zelira conducted an industry standard consumer use study of the RAF FIVE franchise that demonstrated improvement in all the patients during the 28-day study, according to the release, with some showing improvement as early as day 7. 

Grossman said, “I am thrilled to be a part of the new Zelira Dermatology and to have teamed up with Zelira to create Zylorma and the RAF FIVE skin care line. Zelira is already known as a leader in cannabinoid research and development for the medical cannabis market, so when they offered me the opportunity to use my medical expertise alongside their ground-breaking scientific formulations to create a truly new and unique solution for acne, I couldn't pass it up.”

She added that in her medical practice, she has seen the struggle to find effective treatments and is interested in seeing more results from the ongoing study. “I believe that science has just started to skim the surface of the skin-healing properties of cannabinoids; RAF FIVE is only the beginning."

Zelira's Dermatology subsidiary is currently developing several other topical products, anticipated to be launched in 2022 including anti-aging, sexual health/intimacy, and specific skin conditions such as psoriasis.1


1. Zelira launches RAF FIVE acne treatment products through its dermatology focused subsidiary. Published September 23, 2021. Accessed September 27, 2021. https://www.prnewswire.com/news-releases/zelira-launches-raf-five-acne-treatment-products-through-its-dermatology-focused-subsidiary-301383621.html

Related Videos
© 2024 MJH Life Sciences

All rights reserved.